Security
GMAB · GENMAB A/S
GMABNASDAQotherCurrentCIK 1434265Updated Sep 26, 2026
GMAB price & chart
Loading TradingView…
NASDAQ:GMAB on TradingView ↗About the company
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody - drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | 963,000,000Source | 7,844,000,000Source | 4,352,000,000Source | 5,522,000,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | -63,000,000Source | 99,000,000Source | -59,000,000Source | 107,000,000Source |
| AdjustmentsForFinanceCostsUSD | 269,000,000Source | 1,977,000,000Source | — | — |
| AdjustmentsForFinanceIncomeUSD | 408,000,000Source | 4,438,000,000Source | — | — |
| AdjustmentsForIncomeTaxExpenseUSD | -460,000,000Source | -343,000,000Source | -1,067,000,000Source | -1,583,000,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 128,000,000Source | 721,000,000Source | 586,000,000Source | 439,000,000Source |
| GoodwillUSD | 355,000,000Source | 2,535,000,000Source | — | — |
| IncreaseDecreaseInWorkingCapitalDKK | — | — | -1,362,000,000Source | 1,930,000,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | 5,000,000Source | — | 1,000,000Source | 1,000,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 135,000,000Source | 935,000,000Source | 908,000,000Source | 283,000,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 13,000,000Source | 60,000,000Source | 91,000,000Source | 73,000,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 5,500,000,000Source | — | — | — |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | 2,622,000,000Source | 11,279,000,000Source | 10,001,000,000Source | 7,254,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 18,000,000Source | 117,000,000Source | 10,000,000Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 273,000,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 626,000,000Source | 3,790,000,000Source | 3,297,000,000Source | 2,676,000,000Source |
| Total RevenueUSD | 3,720,000,000Source | 21,526,000,000Source | 16,474,000,000Source | 14,595,000,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.22Source | 0.22Source | 0.22Source | 0.22Source |
| AverageEffectiveTaxRatenumber | 0.2Source | 0.14Source | 0.23Source | 0.22Source |
| BasicEarningsLossPerShareUSD per share | 15.5Source | 122.21Source | 66.64Source | 84.45Source |
| CurrentTaxExpenseIncomeUSD | 256,000,000Source | 1,799,000,000Source | 1,301,000,000Source | 1,498,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | 10,000,000Source | — | — | — |
| DepreciationRightofuseAssetsUSD | 17,000,000Source | 102,000,000Source | 87,000,000Source | 74,000,000Source |
| DilutedEarningsLossPerShareUSD per share | 15.37Source | 121.36Source | 66.02Source | 83.65Source |
| EmployeeBenefitsExpenseUSD | 763,000,000Source | 4,344,000,000Source | 3,548,000,000Source | 2,583,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 128,000,000Source | 721,000,000Source | 586,000,000Source | 439,000,000Source |
| FinanceCostsUSD | 269,000,000Source | 1,977,000,000Source | 942,000,000Source | 680,000,000Source |
| FinanceIncomeUSD | 408,000,000Source | 4,438,000,000Source | 1,258,000,000Source | 1,358,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | 0Source | 0Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | 241,000,000Source | 1,320,000,000Source | 1,285,000,000Source | 1,513,000,000Source |
| NetForeignExchangeLossDKK | — | 1,594,000,000Source | 889,000,000Source | — |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 34,000,000Source | 205,000,000Source | 170,000,000Source | 112,000,000Source |
| ProfitLossBeforeTaxUSD | 1,204,000,000Source | 9,164,000,000Source | 5,637,000,000Source | 7,035,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | 1,065,000,000Source | 6,703,000,000Source | 5,321,000,000Source | 6,357,000,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,606,000,000Source | 9,748,000,000Source | 7,630,000,000Source | 5,562,000,000Source |
Filing attachments
gmab_20260924xex99d1.htm · 6-K · 2026-09-24
Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 24, 2026 - Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The …
Read attachment ↗